查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844139

药物递送和基因递送装置市场（按技术、装置类型、分子类型、最终用户、应用和治疗领域划分）－2025-2032年全球预测

Drug & Gene Delivery Devices Market by Technology, Device Type, Molecule Type, End User, Application, Therapeutic Area - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，药物输送和基因输送设备市场将成长至 110.6 亿美元，复合年增长率为 11.03%。

主要市场统计数据
基准年 2024 47.9亿美元
预计年份：2025年 53.2亿美元
预测年份：2032年 110.6亿美元
复合年增长率 (%) 11.03%

对药物递送和基因递送装置领域进行策略性介绍，重点关注材料创新、数位化系统、不断变化的监管环境以及患者需求。

现代药物递送和基因递送装置的格局是由材料创新、数位化以及对患者疗效的持续关註三者融合而成。生物材料的最新进展，结合微型电子元件和整合感测器，为精准给药、封闭式递送和远端监测创造了新的机会。同时，监管预期和报销框架也在不断发展，以适应组合药物和数位化扩展疗法，这要求装置开发人员从一开始就将临床、技术和商业性因素整合起来。

本部分探讨了科学创新与实际应用之间的相互作用。它重点阐述了多学科团队的重要性，这些团队汇集了聚合物科学家、配方专家、机械工程师、软体工程师和临床相关人员，共同开发差异化的给药方案。此外，本部分也指出，病患体验作为设计驱动因素的作用日益凸显，易用性、安全性和依从性如今直接影响药物的采纳。最后，本部分透过阐明决定未来几年哪些技术和经营模式能够成功的关键因素，为后续的详细分析奠定了基础。

材料突破、数位化工具、製造创新和监管动态正在发生变革性转变，再形成药物传输和基因输送装置。

变革性的转变正在重塑药物和基因传递装置的竞争格局和技术格局。材料科学的突破，例如先进水凝胶、脂质奈米颗粒系统和多功能聚合物，正在催生新的製剂和控制释放方案。同时，数位化工具和嵌入式感测器正在将装置从被动载体转变为智慧平台，为临床医生和支付方提供剂量智慧、依从性回馈和真实世界资料流。

模组化、可扩展生产方式和本土化能力的投资正在缩短复杂交付系统的前置作业时间并提升品管。监理预期也在同步变化，监理机关更重视综合风险管理、连网型设备的网路安全以及生命週期资料。总而言之，这些转变有利于那些将深厚的材料专业知识与系统工程、可靠的临床证据产生以及灵活的监管策略相结合的企业。因此，多学科融合而非单一技术优势将决定可持续的差异化优势。

评估2025年美国关税对供应链、零件采购、定价策略和製造业韧性的累积影响

美国宣布并实施的关税政策将持续到2025年，将对药物输送和基因输送设备生态系统产生多方面的影响。关税将改变零件采购的经济格局，使一些进口材料和次组件价格上涨，并促使企业寻求替代筹资策略。这项变更将迫使製造商和设备开发商重新评估其供应商组合，考虑更近的采购方案，并加快二级供应商的资格认证，以降低单一来源风险。

除了直接的成本影响外，关税还会影响企业在製造和最终组装方面的策略决策。拥有灵活模组化製造架构的企业更有能力调整生产布局，以应对投入成本的波动。采购团队需要重新调整整体拥有成本模型，将关税、物流波动和前置作业时间延长等因素的影响纳入考量。重要的是，在采购模式转变的过程中，也必须预先考虑监理申报和供应商变更管理等问题。最终结果是，供应链韧性和本地化能力建设将再次成为设备製造商及其合作伙伴的核心策略重点。

透过细分市场分析，深入了解技术选择、设备类型、分子类别、最终用户、应用和治疗重点如何影响设计和采用。

严谨的细分方法揭示了不同技术平台、器械形式、分子类别、治疗环境、应用目标和治疗重点在设计选择和商业化路径上的差异。技术研究着重于水凝胶、脂质体、奈米颗粒和聚合物基平台，每种平台都具有独特的释放动力学、稳定性特征以及对敏感生技药品和基因疗法的兼容性考虑。这些材料选择直接影响器械结构、无菌策略和低温运输要求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用穿戴式电化学感测器优化胰岛素持续给药
  • 用于靶向体内基因编辑的基于 CRISPR 的新型脂质奈米颗粒製剂
  • 将人工智慧预测模型整合到智慧输液帮浦中，用于个人化肿瘤治疗
  • 开发用于局部化疗传递的超音波触发微气泡载体
  • 用于持续释放肽类药物的可生物降解聚合物植入的研究进展
  • 利用自扩增mRNA脂质奈米颗粒增强免疫疗法
  • 可扩展基因治疗载体生产的品质源自于设计方法的监管协调

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 按技术分類的药物传输和基因传输设备市场

  • 水凝胶基
  • 脂质体
  • 奈米颗粒
  • 聚合物基

9. 按设备类型分類的药物传输和基因传输设备市场

  • 自动喷油器
  • 点滴帮浦
  • 无针注射器
  • 笔式註射器
  • 注射器

10. 依分子类型分類的药物递送和基因递送装置市场

  • 生技药品
    • 单株抗体
    • 胜肽
    • 重组蛋白
  • 基因治疗
    • 非病毒性
      • 基于脂质的
      • 聚合物基
    • 病毒载体
      • 腺病毒
      • 慢病毒
      • 逆转录病毒
  • 小分子

11. 按最终用户分類的药物传输和基因传输设备市场

  • 诊所
  • 家庭医疗保健
  • 医院
  • 实验室

12. 按应用分類的药物传输和基因传输设备市场

  • 控释
  • 智慧配送
  • 缓释
  • 定向投放

13. 按治疗领域分類的药物传递和基因传递设备市场

  • 心血管系统
  • 糖尿病
  • 感染疾病
  • 肿瘤学

14. 各地区药物传输及基因传递设备市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. 按组别分類的药物传输和基因传输设备市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国药物传输与基因传递设备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Becton Dickinson and Company
    • West Pharmaceutical Services, Inc.
    • Terumo Corporation
    • Gerresheimer AG
    • Baxter International Inc.
    • Nipro Corporation
    • Stevanato Group SpA
    • SHL Medical AG
    • Ypsomed Holding AG
    • Lonza Group AG
Product Code: MRR-A86604082727

The Drug & Gene Delivery Devices Market is projected to grow by USD 11.06 billion at a CAGR of 11.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.79 billion
Estimated Year [2025] USD 5.32 billion
Forecast Year [2032] USD 11.06 billion
CAGR (%) 11.03%

Strategic introduction to the drug and gene delivery device landscape highlighting materials innovation, digital systems, regulatory change, and patient needs

The modern drug and gene delivery device landscape is defined by a convergence of materials innovation, digital enablement, and a relentless focus on patient outcomes. Recent advances in biomaterials, coupled with miniaturized electronics and embedded sensors, have created new opportunities for precision dosing, closed-loop delivery, and remote monitoring. At the same time, regulatory expectations and reimbursement frameworks are evolving to account for combination products and digitally augmented therapeutics, requiring device developers to integrate clinical, technical, and commercial considerations from the outset.

This introduction frames the interplay between scientific innovation and practical deployment. It highlights how cross-disciplinary teams-bringing together polymer scientists, formulation experts, mechanical and software engineers, and clinical stakeholders-are now required to develop differentiated delivery solutions. The narrative also recognizes the growing role of patient experience as a design driver: ease of use, safety, and adherence now directly influence adoption. Finally, the section sets a foundation for the deeper analyses that follow, establishing the critical dependencies that will determine which technologies and business models succeed in the coming years.

Transformative shifts reshaping drug and gene delivery devices through materials breakthroughs, digital tools, manufacturing innovation, and regulatory dynamics

Transformative shifts are reshaping the competitive and technical landscape for drug and gene delivery devices. Materials science breakthroughs such as advanced hydrogels, lipid nanoparticle systems, and multifunctional polymers are enabling new formulations and controlled-release profiles. Concurrently, digital tools and embedded sensors are transitioning devices from passive carriers to intelligent platforms that provide dosing intelligence, adherence feedback, and real-world data streams for clinicians and payers.

Manufacturing innovation is another vector of change: modular, scalable production approaches and investments in onshore capabilities are reducing lead times and improving quality control for complex delivery systems. Regulatory expectations are moving in parallel, with authorities placing greater emphasis on integrated risk management, cybersecurity for connected devices, and lifecycle data. Taken together, these shifts favor organizations that combine deep materials expertise with systems engineering, robust clinical evidence generation, and nimble regulatory strategies. The result is a landscape where multidisciplinary integration, rather than single-technology advantage, determines sustainable differentiation.

Assessing cumulative effects of United States tariffs for 2025 on supply chains, component sourcing, pricing strategies, and manufacturing resilience

The announcement and implementation of United States tariffs for 2025 introduces a multi-dimensional effect on the drug and gene delivery device ecosystem. Tariffs alter the economics of component sourcing, making some imported materials and subassemblies more expensive and incentivizing alternative sourcing strategies. This change forces manufacturers and device developers to re-evaluate supplier portfolios, consider nearer-shore options, and accelerate qualification of secondary suppliers to mitigate single-source risk.

Beyond immediate cost implications, tariffs can influence strategic decisions about where to locate manufacturing and final assembly. Firms with flexible, modular manufacturing architectures are better positioned to shift production footprints and absorb input-cost variability. Procurement teams will need to rework total-cost-of-ownership models to incorporate tariff impacts, logistics volatility, and longer lead times. Importantly, regulatory submissions and supplier change controls must be anticipated as part of these sourcing shifts. The net effect is a renewed emphasis on supply chain resilience and localized capability development as core strategic priorities for device makers and their partners.

Segmentation insights on how technology selection, device types, molecule classes, end users, applications, and therapeutic focus shape design and adoption

A disciplined segmentation approach reveals where design choices and commercialization pathways diverge across technology platforms, device formats, molecular classes, care settings, application goals, and therapeutic priorities. Based on Technology, studies focus on Hydrogel Based, Liposomal, Nanoparticle, and Polymer Based platforms, each offering distinct release kinetics, stability profiles, and compatibility considerations for sensitive biologics and gene therapies. These material choices directly shape device architecture, sterility strategies, and cold-chain requirements.

Based on Device Type, analysis spans Auto Injector, Infusion Pump, Needle Free Injector, Pen Injector, and Syringe formats; device ergonomics, actuation mechanisms, and safety interlocks vary significantly across these forms and create different barriers to entry. Based on Molecule Type, the landscape distinguishes Biologic, Gene Therapy, and Small Molecule programs. The Biologic category further breaks into Monoclonal Antibody, Peptide, and Recombinant Protein, each with unique handling and delivery constraints. The Gene Therapy segment is split between Non Viral and Viral Vector approaches, where Non Viral divides into Lipid Based and Polymer Based carriers and Viral Vector workstreams include Adenoviral, Lentiviral, and Retroviral vectors-factors that influence manufacturing complexity, regulatory pathways, and cold-chain logistics.

Based on End User, insights cover Clinics, Home Healthcare, Hospitals, and Research Laboratories, highlighting different training, support, and device maintenance requirements. Based on Application, analysis evaluates Controlled Release, Smart Delivery, Sustained Release, and Targeted Delivery objectives and how they map to therapeutic intent. Based on Therapeutic Area, the review emphasizes Cardiovascular, Diabetes, Infectious Diseases, and Oncology, each bringing distinct clinical endpoints, dosing windows, and payer dynamics that shape product design and evidence strategies. Together, these segmentation dimensions create an analytical scaffolding for prioritizing investments and tailoring commercialization approaches to specific clinical and market realities.

Regional view of adoption, regulatory climate, manufacturing capabilities, and commercialization across Americas, Europe, Middle East & Africa, Asia-Pacific

Regional dynamics exert a profound influence on adoption timing, regulatory approach, manufacturing strategy, and commercialization pathway. In the Americas, there is a strong emphasis on rapid commercialization, large-scale clinical validation, and integrated care pathways that support device-enabled therapeutics; market entrants often prioritize scalable manufacturing and robust post-market surveillance. In Europe, Middle East & Africa, regulatory heterogeneity and national reimbursement systems require tailored market access strategies, localized clinical evidence, and partnerships with regional distributors to navigate fragmented procurement environments.

In Asia-Pacific, growth is frequently driven by a mix of local innovation hubs, cost-sensitive manufacturing, and rapidly expanding home-health adoption, all of which favor cost-effective, user-friendly devices that can be deployed at scale. Across these regions, differences in supply chain resilience, talent availability, and standards for clinical data shape where companies choose to invest in production capacity, R&D, and commercial teams. Companies that align regulatory strategy, manufacturing footprint, and commercialization priorities with these regional nuances can accelerate market entry and reduce unforeseen compliance or logistics risks.

Company-level insights on strategic alliances, technology portfolios, manufacturing investments, regulatory positioning, and competitive differentiation

Company-level strategies are increasingly centered on ecosystem plays that combine proprietary technologies with strategic partnerships. Leaders invest selectively in platform technologies that can be adapted across multiple device types and therapeutic areas, while also building alliances with contract manufacturers, formulation specialists, and digital health vendors. These collaborations reduce time-to-market for complex combination products and distribute technical risk across a broader partner network.

Investment decisions hinge on demonstrable differentiation: robust IP in delivery mechanisms, validated compatibility with high-value molecules such as monoclonal antibodies or viral vectors, and a credible path to regulatory approval. Firms that disclose clear manufacturing roadmaps, including plans for scale-up and quality systems alignment, tend to attract more favorable partnerships and procurement opportunities. Equally important is a company's ability to generate clinician and patient-centric evidence demonstrating improved adherence, reduced complications, or streamlined care pathways. This evidence underpins discussions with payers and health systems and becomes a decisive factor in adoption and reimbursement conversations.

Practical recommendations for industry leaders to prioritize technologies, refine device design, fortify supply chains, and elevate patient care strategies

Industry leaders should take decisive actions to convert insight into competitive advantage. Prioritize investments in platform technologies that demonstrate cross-therapeutic applicability and compatibility with sensitive biologics and gene vectors, and allocate R&D resources to integrate digital functions that measurably improve adherence and clinical outcomes. Strengthen supplier relationships by qualifying multiple sources for critical components and by developing nearer-shore or dual-source strategies to reduce exposure to global tariff and logistics disruptions.

Refine device design by centering human factors and real-world use cases early in development to ensure high usability across Clinics, Home Healthcare, and Hospitals. Align regulatory strategy with evidence-generation plans that can support combination product submissions and address cybersecurity expectations for connected devices. Finally, embed commercialization thinking into product development so that clinical evidence, pricing models, and distribution approaches evolve in parallel with technical milestones; this reduces go-to-market friction and accelerates payer and provider conversations.

Research methodology outlining data sources, primary and secondary research steps, validation protocols, and analytical frameworks applied to device assessment

The research methodology integrates primary interviews, targeted technical validation, and secondary research to build a robust evidence base. Primary research includes structured interviews with executives, R&D leaders, regulatory specialists, manufacturing partners, and clinicians to capture real-world constraints, adoption drivers, and unmet needs. Secondary research encompasses peer-reviewed literature, regulatory guidance documents, patent filings, and corporate disclosures to triangulate technical capabilities and historical precedent.

Validation protocols involve cross-checking interview findings against public filings and regulatory submissions, while analytical frameworks combine technology readiness assessments, supply chain risk scoring, and adoption-mapping exercises. Data synthesis emphasizes reproducibility and auditability: assumptions are documented, sensitivity analyses are conducted where appropriate, and methodological limitations are clearly stated. This layered approach ensures that conclusions rest on multiple evidence streams and that recommendations are actionable for R&D, regulatory, and commercial stakeholders.

Concluding synthesis highlighting strategic priorities, technology trends, regulatory context, and the need to align device design with patient and market realities

The conclusion synthesizes the strategic imperatives uncovered across materials platforms, device modalities, supply chain realities, and regional dynamics. It emphasizes that success in the drug and gene delivery device space requires integrated thinking: technical differentiation must be coupled with manufacturing scalability, regulatory foresight, and commercialization readiness. Stakeholders that coordinate these elements early in the product lifecycle are better positioned to navigate approval pathways, secure favorable procurement, and demonstrate real-world value to clinicians and payers.

Looking ahead, the most sustainable advantages will accrue to organizations that can combine platform extensibility with evidence-generation frameworks that speak to both clinical outcomes and total cost of care. Companies should view device development not as a one-off engineering challenge but as an end-to-end program that links scientific innovation to patient experience and market access. This alignment is the core determinant of long-term adoption and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of wearable electrochemical sensors for continuous insulin dosing optimization
  • 5.2. Emergence of CRISPR-based lipid nanoparticle formulations for targeted in vivo gene editing
  • 5.3. Integration of AI predictive models in smart infusion pumps for personalized oncology therapies
  • 5.4. Development of ultrasound-triggered microbubble carriers for localized chemotherapeutic delivery
  • 5.5. Advancements in biodegradable polymeric implants for sustained release of peptide therapeutics
  • 5.6. Use of self-amplifying mRNA lipid nanoparticles for enhanced immunotherapy applications
  • 5.7. Regulatory alignment on quality-by-design approaches for scalable gene therapy vector manufacturing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug & Gene Delivery Devices Market, by Technology

  • 8.1. Hydrogel Based
  • 8.2. Liposomal
  • 8.3. Nanoparticle
  • 8.4. Polymer Based

9. Drug & Gene Delivery Devices Market, by Device Type

  • 9.1. Auto Injector
  • 9.2. Infusion Pump
  • 9.3. Needle Free Injector
  • 9.4. Pen Injector
  • 9.5. Syringe

10. Drug & Gene Delivery Devices Market, by Molecule Type

  • 10.1. Biologic
    • 10.1.1. Monoclonal Antibody
    • 10.1.2. Peptide
    • 10.1.3. Recombinant Protein
  • 10.2. Gene Therapy
    • 10.2.1. Non Viral
      • 10.2.1.1. Lipid Based
      • 10.2.1.2. Polymer Based
    • 10.2.2. Viral Vector
      • 10.2.2.1. Adenoviral
      • 10.2.2.2. Lentiviral
      • 10.2.2.3. Retroviral
  • 10.3. Small Molecule

11. Drug & Gene Delivery Devices Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Research Laboratories

12. Drug & Gene Delivery Devices Market, by Application

  • 12.1. Controlled Release
  • 12.2. Smart Delivery
  • 12.3. Sustained Release
  • 12.4. Targeted Delivery

13. Drug & Gene Delivery Devices Market, by Therapeutic Area

  • 13.1. Cardiovascular
  • 13.2. Diabetes
  • 13.3. Infectious Diseases
  • 13.4. Oncology

14. Drug & Gene Delivery Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Drug & Gene Delivery Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Drug & Gene Delivery Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Becton Dickinson and Company
    • 17.3.2. West Pharmaceutical Services, Inc.
    • 17.3.3. Terumo Corporation
    • 17.3.4. Gerresheimer AG
    • 17.3.5. Baxter International Inc.
    • 17.3.6. Nipro Corporation
    • 17.3.7. Stevanato Group S.p.A.
    • 17.3.8. SHL Medical AG
    • 17.3.9. Ypsomed Holding AG
    • 17.3.10. Lonza Group AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG & GENE DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHN